Cellosaurus logo
expasy logo

Cellosaurus HT1080/DR4 (CVCL_6C48)

[Text version]
Cell line name HT1080/DR4
Accession CVCL_6C48
Resource Identification Initiative To cite this cell line use: HT1080/DR4 (RRID:CVCL_6C48)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
Sequence variations
  • Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
Disease Fibrosarcoma (NCIt: C3043)
Fibrosarcoma (ORDO: Orphanet_2030)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0317 (HT-1080)
Sex of cell Male
Age at sampling 35Y
Category Cancer cell line

Slovak M.L., Hoeltge G.A., Dalton W.S., Trent J.M.
Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Cancer Res. 48:2793-2797(1988)

PubMed=1976136; DOI=10.1093/jnci/82.19.1553
Zwelling L.A., Slovak M.L., Doroshow J.H., Hinds M., Chan D., Parker E., Mayes J., Sie K.L., Meltzer P.S., Trent J.M.
HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
J. Natl. Cancer Inst. 82:1553-1561(1990)

Slovak M.L., Coccia M., Meltzer P.S., Trent J.M.
Molecular analysis of two human doxorubicin-resistant cell lines: evidence for differing multidrug resistance mechanisms.
Anticancer Res. 11:423-428(1991)

Cell line databases/resources cancercelllines; CVCL_6C48
Encyclopedic resources Wikidata; Q54896569
Entry history
Entry creation23-Feb-2016
Last entry update05-Oct-2023
Version number15